Search
EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)
Dates: February 4-6, 2021
Chairs: H Einsele (EHA) & C Chabannon (EBMT)
For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Read morePress release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013
In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.
Read moreTravel Grants
Application for a travel grant closed on August 29
Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and are reserved for applicants from upper-middle, lower-middle, and low-income countries.
National societies
EHA pursues close collaboration with the national hematology societies to ensure that the professional hematology community in Europe is served in the best possible way.
Read moreSWG Educational Activities
MeetingsSWG meetingsThe SWG on Transfusions holds monthly meetings. EHA CongressOne focus is support for all activities of the EHA Congress. At the EHA 2023 Congress, which was held in Frankfurt, some sessions on transfusion were supported virtually.
Read moreRegulatory affairs & scientific relations
EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).
Read moreNikolai Klimko 1956-2023
Professor Nikolai Klimko
Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023
With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.
Clinical trials
The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- »